Welcome to the Emerging Drugs and Technologies Conclave to be held at Hotel Hycinth, Trivandrum on 1 & 2nd of April 2017. The science of diabetes is now dominated by newer therapies and technological advances. The practicing physician should learn and adopt these technologies to keep in touch with this ever-changing science. The slow adoption on these drugs and technologies is a proof to the lingering doubts and cautions.

This symposium focusses on these nuances. From reading and interpreting clinical trials to emerging technologies like CGMS, pumps and novel mechanisms of drug action, this meeting has all it takes to keep you engaged for 8 hours. Some of the best speakers and academicians in the diabetes space have travelled to Thiruvananthapuram to make this event a great academic feast. The topics are very focused to help the serious practitioners of diabetes.

Dr. Mathew John

Emerging Drugs and Technologies Conclave

Day 1 Saturday / April 1 /2017

Dr. Tittu Oommen,Dr. Sunil Prashobh

– Drug development in diabetes: what are the challenges? Dr. Krishna G. Seshadri,
– LEADER, SUSTAIN and EMPA –REG: a critical analysis? Dr. A.K. Singh, Kolkatta
– The global scenario of concentrated insulins : Dr. Rajiv Kovil

7:30-9:00PM Gliptin symposium SPONSOR: MSD
Dr. Harikrishnan, Dr. Sasikumar

– Will CVOT’s influence my choice of DPP4 inhibitor ?Dr. Santhosh Ramakrishnan
– Heart failure in CV outcome trials: clinical implications: Dr. A. K. Singh, Kolkatta
– Role of DPP 4 inhibitors with the advent of SGLT2 blockers: Dr. A.G. Unnikrishnan

Day 2: Sunday: 9 AM -10:30 AM /April 2

9:00-10:00 AM: IV. Newer Insulin Symposium
Dr. Dinesh Prabhu, Dr. Prashanth Shankar

– Patient selection for newer insulins: who is the right patient for Degludec, IDeg Asp and U300 Glargine?
   Dr. Vagesh Ayyer
– Intensifying basal insulin therapy: patient selection for GLP-1R vs. prandial insulin: Dr. Manoj Chawla

10:00-11:30 PM SGLT2 inhibitors symposium AZTRA ZENECA
Chair persons:Dr. Anita Nambiar,Dr. Deepa G

– CV outcomes with SGLT2 blockers: mechanisms and controversies : Dr. Krishna G. Seshadri
– Renal protection with SGLT2 inhibitors: can we buy into it? Dr. Jyothish Gopinathan
– Are SGLT2i a preferred choice for Asian Indian phenotypes? 20 min Dr. Anatharaman Ramakrishnan

11: 30—1:00 Modern Retro
Chair persons: Dr. Sabeer Rashid, Dr. Maneesh Unnithan

– Statistics of drug trials: for clinicians: Dr. Tiny Nair
– Do we need a new classification for diabetes? Dr. Joe George
– Using CGMS in clinical practice: interpreting and making therapeutic changes: Dr. Manoj Chawla
– Insulin pumps in type 2 diabetes: evidence and experience :Dr. Jothydev Kesavadev

01:00-2:00 PM: GLP-1 receptor agonists
Chair persons: Dr. Arun Shankar

– Exploiting differences between GLP-1 receptor agonists for better therapeutic outcomes : 20 min :
   Dr.Santhosh Ramakrishnan
– GLP-1 –Basal Insulin fixed dose combinations: patient selection: 20 min :Dr. Vageesh Ayyar